Molecular analysis of HLA-DQB1 alleles in childhood common acute lymphoblastic leukaemia

SP Dearden¹, GM Taylor¹, DA Gokhale¹, MD Robinson¹, W Thompson², W Ollier³, A Binchy³, JM Birch³, RF Stevens³, T Carr⁴ and WG Bardsley⁴

¹Immunogenetics Laboratory, St Mary’s Hospital; ²ARC Epidemiology Unit, University of Manchester; ³CRC Paediatric Cancer Research Group and ⁴Paediatric Haematology/Oncology Unit, Royal Manchester Children’s Hospital, Pendlebury, Manchester; ⁵Department of Cell and Structural Biology, University of Manchester, UK.

Summary. Epidemiological studies suggest that childhood common acute lymphoblastic leukaemia (c-ALL) may be the rare outcome of early post-natal infection with a common infectious agent. One of the factors that may determine whether a child succumbs to c-ALL is how it responds to the candidate infection. Since immune responses to infection are under the partial control of (human leucocyte antigen) HLA genes, an association between an HLA allele and c-ALL could provide support for an infectious aetiology. To define the limit of c-ALL susceptibility within the HLA region, we have compared HLA–DQβ1 allele frequencies in a cohort of 62 children with c-ALL with 76 newborn controls, using group-specific polymerase chain reaction (PCR) amplification, and single-strand conformation polymorphism (SSCP) analysis. We find that a significant excess of children with c-ALL type for DQB1*05 [relative risk (RR): 2.54, uncorrected 95% CI 0.038, and a marginal excess with DQB1*0501 (RR: 2.18; 95% CI 0.059). Only 3 of the 62 children with c-ALL have the other susceptibility allele, DQB1*0201, as well as DQB1*0501, whereas 15 had one or the other allele. This suggests that HLA-association susceptibility may be determined independently by at least two loci, and is not due to linkage disequilibrium. The combined relative risk of the two groups of children with DPBI*0201 and/or DQB1*0501 is 2.76 (95% CI 0.0706). Analysis of amino acids encoded by exon 2 of DQB1 reveal additional complexity, with significant (P<0.05) or borderline-significant increases in Gly26, His30, Val37, Glu66-Val67 encoding motifs in c-ALL compared with controls. Since these amino acids are not restricted to DQB1*0501, we suggest that, as with DPB1, the increased risk of c-ALL associated with DQB1 is determined by specific amino acid encoding motifs rather than by an individual allele. These results also suggest that HLA-associated susceptibility to c-ALL may not be restricted to the region bounded by DPB1 and DQB1.

Keywords: childhood common acute lymphoblastic leukaemia; HLA–DQB1; genetic susceptibility; infectious aetiology

Childhood acute lymphoblastic leukaemia (ALL) is the most frequently occurring leukaemia among children of the developed countries (Breslow and Langholz, 1983; Parkin et al., 1988; Linet and Devesa, 1991). A unique feature of ALL in white Caucasian children is the peak number of cases that occurs between the ages of 2 and 5 years (Stewart, 1961; Parkin et al., 1988; Linet and Devesa, 1991). This first appeared in the UK as a mortality peak after 1920 (Court Brown and Doll, 1961), and has remained to the present as an incidence peak, despite a marked reduction in mortality in the past 3 decades. Immunophenotyping has shown that this early peak is almost entirely due to the B-cell precursor form of common ALL (c-ALL) (Greaves, Pegram and Chan, 1985). Suggestions that the c-ALL peak was unmasked following a decline in pre-emptive childhood mortality from infectious disease between the early 1900s and 1940 (Stewart and Kneale, 1969; Kneale, 1971) have been questioned by Greaves et al. (1991) on the grounds that no similar increase in other subtypes of childhood acute leukaemia has been seen.

The role of infection in the aetiology of childhood ALL has recently been re-examined in relation to its cell biology, the timing of post-natal infection (Greaves and Alexander, 1993) and population mixing (Kinlen et al., 1990), and has suggested that childhood c-ALL may be the rare outcome of a common but unidentified neonatal infection. This poses questions about the contribution of potentially rate-limiting host factors such as genetic susceptibility (Taylor, 1994). In order to determine whether these could involve immune response genes, we previously analysed the frequency of HLA–DPB1 alleles in c-ALL, and found an increased risk in children with HLA–DPB1*0201 [relative risk (RR) 2.1–2.9] (Taylor et al., 1995).

To try to define the physical limit of genetic susceptibility within the HLA region, we have now typed the same cohort of children for alleles at the HLA–DQB1 locus. This is a related HLA class II gene approximately 420 kb telomeric to DPB1 (Trowsdale and Campbell, 1992). DQB1 alleles are associated with susceptibility and resistance to several malignant and non-malignant diseases notably adult T-ALL (Uno et al., 1988), cervical intraepithelial neoplasia and human papilloma virus (HPV) (Apple et al., 1994), type 1 (insulin-dependent) diabetes mellitus (Todd, Bell and McDee, 1987) and melanoma (Lee et al., 1994). We report that children who have DQB1*0501 are at increased risk of c-ALL, and that this does not appear to be in linkage disequilibrium with DPB1*0201. We also find that as with DPB1, the increased risk associated with DQB1 is strongest in relation to key amino acid motifs rather than with individual alleles.

Materials and methods

Patients and controls

The patients in this study comprise the same cohort as that described previously (Taylor et al., 1995) and consists of 62 children (one child from the previous study is excluded) with c-ALL treated at a single centre (Royal Manchester Children’s Hospital) in the north west of England, between 1990 and 1992. To reduce bias to an absolute minimum, only children in whom a diagnosis of c-ALL was confirmed by cytology and immunophenotyping according to the Medical Research Council’s 11th ALL trial (UKALL XI) guidelines are included in the analysis. Patients with other leukaemia
subtypes, including those with unclassified ALL are excluded. Blood samples were obtained from children, usually in remission, either in the clinic or at home with parental consent. The blood was anticoagulated with EDTA, and frozen before DNA extraction within 12 h of donation. Control blood samples were obtained from the placental side of the clamped umbilical cord of normal full-term babies delivered at St Mary's Hospital. Preterm deliveries, caesarean sections and pregnancies with complications were excluded.

DNA extraction and amplification

Genomic DNA was extracted from fresh or frozen blood samples using established methods (Blin and Stafford, 1976), and an exon 2 fragment of DQB1 amplified in the polymerase chain reaction (PCR; Erlich and Arnheim, 1992) using the oligonucleotide primers depicted in Table I and Figure 1. These DQB1 locus-specific primers do not amplify the related but non-expressed DQB2 or DQB3 genes. The primers were designed to amplify four groups of alleles (nomenclature according to WHO guidelines): the *02/*03 group (0201, 0301, 0302, 0303, 0304), the *04 group (0401, 0402), the *05 group (0501, 0502, 0503, 0504) and the *06 group (0601, 0602, 0603, 0604, 0605, 0606, 0607, 0608).

DQB1 amplifications were carried out in mixtures consisting of 50 ng genomic DNA, 2 µl 10 × PCR buffer (500 mM potassium chloride, 100 mM Tris-HCl, pH 8.8, 1% Triton X-100), 2 µl 25 mM primer mix, 3 µl 2 mM dNTP mixture, 2.4 µl 25 mM magnesium chloride, 0.5 µl Taq DNA polymerase (Promega, Madison WI, USA), and sterile distilled water to 20 µl. Reaction mixtures were overlaid with 20 µl of Chill-Out liquid wax (Scotlab, Strathclyde, UK), and were denatured at 94°C for 150 s followed by 36 cycles of denaturation (94°C, 45 s) annealing/extension (58°C, 45 s) and a final extension step (74°C, 180 s), using a thermal cycler (Crocoddle II, Appligene, France). The reaction products were monitored by electrophoresis on 0.8% agarose minigels.

Single-strand conformation polymorphism (SSCP) typing

DQB1 alleles were detected using the SSCP method described by Orita et al. (1989), modified for HLA-DQB1 typing as described by Lo et al. (1992) and Summers et al. (1992). For this, 15 µl of each PCR product was mixed with 2 µl of loading dye (0.5% bromophenol blue, 0.5% xylene cyanol in deionised formamide), and heated to 95°C for 10 min to denature the DNA and reduce the sample volume to 4–5 µl. The samples were loaded onto non-denaturing polyacrylamide gels (PAGs) in a water-cooled vertical mini-electrophoresis unit (Cambridge Electrophorases, Cambridge, UK). SSCP conditions for all group-specific PCR products were the same, including the ratio of acrylamide–methylenebisacrylamide (39:1), which was prepared from stock Easigel mix (Scotlab, Strathclyde, UK) and solid acrylamide (BDH, Lutterworth, UK). SSCP gels were run using 0.5X TBE and 0.8 mm spacers, at 9 mA constant current. SSCP band patterns were visualised using silver staining (Qiagen, Düsseldorf, Germany) following the manufacturer’s instructions and photographed using a 35 mm SLR camera without filters and Agfa Ortho film.

Data analysis

DQB1 allele frequencies in c-ALLs and controls were calculated as percentages of total alleles. Phenotype frequencies were determined as the percentage of test subjects with a given allele in either homozygous or heterozygous form. Genotype frequencies were obtained by calculating the proportion of individuals with combinations of two alleles. Relative risks (RRs) were obtained by the cross-product odds ratio method, and these were tested for significance using 2 × 2 (χ²) contingency analysis using SIMFIT. Since this study was used for hypothesis generation, no correction for the number of alleles tested has been applied.

Results

DQB1 molecular typing

In preliminary studies to optimise DQB1 molecular typing, we used generic primers obtained from the British Society for Histocompatibility and Immunogenetics (BSHI) to amplify exon 2 from genomic template DNA, and BSHI-derived sequence specific oligonucleotide (SSO) probes to detect specific alleles. However, in our hands, we were unable to distinguish certain DQB1 alleles using this system. We therefore designed a set of nine primers as shown in Table I and Figure 1, which we used in various combinations to amplify groups of alleles, and SSCP analysis to distinguish the alleles within each group. Using this method we were also able to confirm and clarify DQB1 allele assignments obtained on HL4 homozygous and heterozygous test cells typed with generic primers and SSO probes. All pairs of group-specific primers were found to amplify in the predicted manner according to Table I. No amplification of other allelic groups was obtained, and it was not necessary to introduce deliberate mismatches into the primer sequences to improve specificity.

The results in Figure 2 show SSCP band patterns obtained with the DQB1 02/03 group-specific primers on homozygous and heterozygous cells. They are distinct enough to allow alleles to be assigned in heterozygotes. No DNA was available for the following rare alleles: DQB1*0304, *0605–*0608, but these alleles would have been amplified by our group-specific primers and may give distinct bands.

---

**Table I Sequences of DQB1 primers**

| Primer | Sequence | Codon | Fragment (bp) | Allele |
|--------|----------|-------|---------------|--------|
| 02 group |         |       |               |        |
| P3a    | ACAGGAGGCCTGCAGATTA | 26  | 210 | 0301 |
| P3b    | ACAGGAGGCCTGCAGCTCT  | 26  | 210 | 0301/0302 |
| P3R    | CAAGGCTGTGGGGAAGCT    | 86  |     |        |
| 04 group |         |       |               |        |
| P4a    | TCCCGGAGAGTCTGTTTGA   | 9   | 235 | 0401/0402 |
| P4b    | ACCACGGGACCGAGCT      | 23  | 195 | 0402 |
| P4R    | GGTGTTGCTGCAAGCTG    | 77  |     |        |
| 05 group |         |       |               |        |
| P5a    | GAGAGGCCCTGCGGGG      | 26  | 206 | All 05s |
| P5R    | GGATCCGCCGCTGACC     | 86  |     |        |
| 06 group |         |       |               |        |
| P3a    | As above            | 204 |  | 0601 |
| P3b    | As above            | 204 |  | 0602/0603, 0604 |

*P3a, P3b, P4a, P4b, P5 are sense primers; P3R, P4R, P5R, P6S are antisense primers. aCodon number is the 3’ end of each primer.
Table II  HLA-DQB1 allele and phenotype frequency in childhood c-ALL and infant controls

| Allele | c-ALL frequency (%) | Phenotype frequency (%) | RR | P value |
|--------|---------------------|-------------------------|----|---------|
|        | Art 0201            | Infants                 |     |         |
| *0201  | 24.2                | 37.5                    | 43.5| 0.62    |
| *0301  | 17.7                | 15.8                    | 30.6| 1.33    |
| *0302  | 4.8                 | 7.9                     | 9.7 | 0.71    |
| *0303  | 2.4                 | 7.2                     | 4.8 | 0.34    |
| *0401  | 0.0                 | 0.0                     | 0.0 | -       |
| *0402  | 2.4                 | 0.7                     | 4.8 | 3.81    |
| *0501  | 16.9                | 9.2                     | 29.0| 2.18b   |
| *0502  | 0.8                 | 0.0                     | 1.6 | -       |
| *0503  | 0.8                 | 0.0                     | 1.6 | -       |
| *0504  | 0.0                 | 0.0                     | 0.0 | -       |
| *0601  | 6.5                 | 3.3                     | 12.9| 2.1     |
| *0602  | 12.9                | 12.5                    | 19.4| 1.06    |
| *0603  | 6.5                 | 4.0                     | 12.9| 2.1     |
| *0604  | 4.0                 | 2.0                     | 8.1 | 3.25    |
| n      | 124                 | 152                     | 62  | 76      |

*Phenotype frequencies in which there is a significant difference between c-ALLs and controls. bRelative risk (RR) for which there is borderline significance between c-ALL and controls. *P-value.

DQB1 allele frequency in childhood c-ALL

Details of the children with c-ALL who were typed for DQB1 in this study are given in a previous paper (Taylor et al., 1995). Briefly, 62 children with a confirmed diagnosis of c-ALL, consisting of 36 boys and 26 girls (M/F 1.42:1) with a mean age of 5.6 years and age range of 1–13 years constituted the patient cohort. About one-third of the girls, but nearly half of the boys were diagnosed at 3–4 years of age. Eight of the 62 children with c-ALL were from ethnic minorities, mainly of Asian origin. The present cohort of c-ALLs comprises 83% of children with ALL ascertained by the Manchester Children's Tumour Registry during the study period. The remainder of the ALLs were excluded from the analysis as being other subtypes, or not confirmed as c-ALL.

The control series used here consists of cord blood samples from 76 Caucasian newborn infants delivered in St Mary's between 1990 and 1992. The only subjects excluded from this cohort were preterm and caesarean deliveries and congenital abnormalities. A total of 14 DQB1 alleles were identified by SSCP typing of the patient and control groups and of these, 12 alleles were detected in the c-ALLs and ten in the controls. Alleles missing both from patients and controls included *0401 and *0504, whereas *0502 and *0503 were absent from the control series only. A comparison of allele frequencies (Table II) shows a deficit of DQB1*0201 in c-ALLs compared with the controls (c-ALL, 24.2% vs controls, 37.5%), but an excess of *0501 in c-ALLs (c-ALL, 16.9% vs controls, 9.2%). There is no difference in *0602 frequency in c-ALL and controls, but there is an excess of the combined *0601, *0603 and *0604 alleles in c-ALLs (c-ALLs, 17% vs controls, 9.3%). In addition, the combined frequency of *0302 and *0303 in c-ALL is about half that in the controls (c-ALLs, 7.2% vs controls, 15.1%).

The deficit of *0201 and excess of *0501 alleles in c-ALL is seen more informatively in the phenotype frequency analysis (Table II), which compares the frequency of patients and controls who carry specific alleles. There is a deficit of 11.8% of children with c-ALL who have DQB1*0201, compared with infant controls (c-ALLs vs infants, 43.5% vs 55.3%), although this is not significant. However, 13.2% more children with c-ALLs have *0501 (c-ALLs vs infants, 29% vs 15.8%), and this reaches borderline significance. Moreover if we combine phenotype frequencies of all *05 series alleles (*0501, *0502, *0503), the cumulative RR (2.54) is significant (P = 0.038). In addition, cumulative phenotype frequencies indicate that over twice as many children with c-ALL type for *0601, *0603 or *0604 (c-ALLs vs infants, 33.9% vs 15.8%), and nearly half as many type for *0302 and *0303 (14.5% vs 26.4%).

Since there are nearly 50% more boys than girls in our c-ALL cohort, we examined whether there might be a

Figure 2  Representative SSCP PAG gel showing silver-stained band patterns obtained after amplification with *02/*03 group-specific primers. Other alleles were assigned following PCR-SSCP analysis with other primers.
**Table III**  
**HLA-DQB1 allele and phenotype frequencies in girls and boys with c-ALL**

| Allele | Frequency (%) | Females | Males | Phenotype frequency (%) | Females | Males | Phenotype analysis |
|--------|---------------|---------|-------|-------------------------|---------|-------|--------------------|
| *0201  | 25.0 (12)     | 23.7 (18) | 45.8  | 42.1                    | 0.86    | 6.4 x 10^{-4} | 0.97 |
| *0301  | 20.8 (10)     | 15.8 (12) | 41.7  | 26.3                    | 0.50    | 0.96 | 0.32 |
| *0302  | 4.2 (2)       | 5.3 (4)  | 8.3   | 10.5                    | 1.29    | 0.024 | 0.87 |
| *0303  | 2.1 (1)       | 2.6 (2)  | 4.2   | 5.2                     | 1.28    | 0.169 | 0.68 |
| *0301  | 10.4 (5)      | 21.1 (16) | 16.7  | 36.8                    | 2.92b   | 2.01 | 0.15** |
| *0501  | 0.0 (0)       | 1.3 (1)  | 0.0   | 2.6                     | -       | -    | -     |
| *0602  | 20.8 (10)     | 7.9 (6)  | 33.3  | 10.5                    | 0.24a   | 3.55 | 0.05** |
| *0602  | 6.3 (3)       | 6.6 (5)  | 12.5  | 13.2                    | 1.06    | 0.098 | 0.75 |
| *0604  | 2.1 (1)       | 5.3 (4)  | 4.2   | 10.5                    | 2.71    | 0.174 | 0.676 |

n = 48 76 24 38

* DQB1 genotypes in which there is >10% difference in frequency in females compared with males. **Relative risks for alleles showing an increased or decreased frequency in c-ALL.  P-value.

**Discussion**

In our previous study we found that children with HLA-DPBI*0201 are at twice the risk of developing common ALL as normal (Taylor et al., 1995). Since there is a possibility that the DPBI*0201 is not itself the c-ALL susceptibility gene, but is in linkage disequilibrium with some
other HLA or non-HLA gene, we carried out further molecular studies on the same cohort to try to define the physical limit of susceptibility to c-ALL in the HLA region. The results reported here show that the risk in children who type for the DQBI*05 allele series is similar to that for DPBI*0201. More importantly, this does not seem to be due to linkage disequilibrium between DPBI*0201 and DQBI*0501, since only 3 of the 62 patients typed for both alleles. Lack of linkage disequilibrium between DPBI*0201 and DQBI*0501 is supported by other studies (Baisch and Capra, 1993). Whereas it is still possible that a susceptibility allele linked to these alleles at both loci maps to the DPBI–DQBI interval, we suggest that susceptibility is conferred independently by the two alleles. Moreover, alignment of the amino acids involved in increased DQBI susceptibility (Val69, Asp150, Glu161) does not provide evidence for an overlap with amino acids involved in DQB1 susceptibility.

It is not as easy to distinguish DQB1 alleles by generic PCR amplification and SSO probe hybridisation as it is for DPBI alleles. For this reason, we designed a series of nine DQBI group-specific primers, which were used in various combinations to amplify four allelic groups (*02, *03, *04, and *06). In conjunction with SSCP analysis of the group-specific PCR products, we were able to distinguish 14 DQBI alleles in heterozygotes. Five alleles were not detected in our patient and control series, including *0304, and *0605–*0608, although it is unlikely that they would not be detected by our typing system. DQBI*0304 shares sequences with primers P3a and P3R, and should therefore be amplified by them. Since it differs at several polymorphic positions from other *03 alleles, it should have been resolved by SSCP. DQBI*0605–*0608 should also amplify with the *06 group-specific primers, since P3b is homologous to these alleles at the 5’ end. Although there are no sequence data for the 3’ end of these alleles, we would expect them to resemble the other alleles in the series. The possibility that they may not separate from the other alleles in the group (*0601–*0604) by SSCP would have made little difference to the overall result had they been present.

A number of molecular typing techniques based on PCR–mediated amplification have been devised to detect DQBI alleles. In an early method (Bugawan and Erlich, 1991), a pair of DQBI generic primers and 16 SSO probes were used to distinguish 15 DQBI alleles. However, other authors using this method have favoured a combination of group-specific amplification and SSO-based typing (Malkentin et al., 1991) to improve resolution. The exacting conditions required for SSO probe hybridisation have led to the development of alternative typing methods, including sequence-specific primer (SSP)-based amplification (Olerup, Aldener and Fogdell, 1993; Salazar et al., 1993). While this has the benefit of being both rapid and high resolution, novel alleles within the

| Table V | Comparison of c-ALLs and infant controls with HLA-DPBI*0201 and DQBI*0501 |
|----------|---------------------------------------------------------------|
| Phenotype | Study group<sup>a</sup> | RR | Phenotype | analysis |
|          | c-ALL | Infants |                |              |
| DPBI*0201 + DQBI*0501 + | 3 (4.8) | 3 (4.1) | 1.17 | 0.053 | 0.817 |
| DPBI*0201 + DQBI*0501− | 15 (24.1) | 10 (13.8) | 1.98 | 1.701 | 0.192 |
| DPBI*0201 − DQBI*0501− | 29 (46.7) | 51 (70.8) | 0.36 | 7.046 | 0.003<sup>b</sup> |
| DPBI*0201 − DQBI*0501 + | 15 (24.1) | 8 (11.1) | 2.55 | 3.143 | 0.076 |

<sup>a</sup>Numbers of individuals (% of total) with DPBI and DQBI alleles. <sup>b</sup>Significant difference between c-ALL and infant controls.

| Table VI | DQBI amino acid motif frequency in childhood c-ALL |
|----------|---------------------------------------------------|
| Amino acid position<sup>a</sup> | Motif<sup>b</sup> | Allele frequency (%) | Phenotype frequency (%) | RR | Phenotype analysis |
|          | c-ALL | Infants | c-ALL | Infants |              |
| 13–14 | AM | 24.2 | 19.1 | 41.9 | 31.6 | 1.56 | 1.17 | 0.28 |
|       | GM | 57.3 | 71.7 | 75.8 | 88.2 | 0.42 | 2.82 | 0.09 |
| 26 | GL<sup>b</sup> | 18.5 | 12.5 | 30.6<sup>c</sup> | 15.8<sup>c</sup> | 2.36 | 3.52 | 0.06<sup>d</sup> |
|       | GM | 57.3 | 71.7 | 75.8 | 88.2 | 0.42 | 2.82 | 0.09 |
| 30 | H<sup>b</sup> | 29.0 | 15.1 | 48.4<sup>e</sup> | 23.7<sup>e</sup> | 3.02 | 8.13 | 0.004<sup>d</sup> |
|       | S | 24.2 | 37.5 | 43.5 | 55.3 | 0.62 | 1.43 | 0.23 |
| 57 | Y | 46.8 | 47.4 | 71.0 | 65.8 | 1.27 | 0.22 | 0.64 |
| 66–67 | DI | 33.1 | 43.2 | 56.5 | 57.9 | 0.94 | <0.01 | 0.99 |
|       | EV<sup>b</sup> | 66.9 | 56.6 | 90.3<sup>e</sup> | 71.1<sup>e</sup> | 3.60 | 6.69 | 0.009<sup>d</sup> |
| 70–71 | ED | 2.4 | 0.7 | 4.8 | 1.3 | 3.81 | 0.51 | 0.47 |
|       | GA<sup>b</sup> | 18.5 | 9.2 | 30.6<sup>c</sup> | 15.8<sup>c</sup> | 2.36 | 3.51 | 0.06<sup>d</sup> |
|       | GT | 19.4 | 16.4 | 30.6 | 25.0 | 1.33 | 0.29 | 0.58 |
|       | RK | 24.2 | 37.5 | 43.5 | 55.3 | 0.62 | 1.43 | 0.23 |
|       | RT | 35.5 | 36.2 | 58.1 | 52.6 | 1.25 | 0.22 | 0.64 |
| 86–87 | AF | 25.8 | 19.7 | 40.3 | 31.6 | 1.46 | 0.79 | 0.37 |
|       | EL<sup>b</sup> | 8.5 | 9.2 | 30.6<sup>c</sup> | 15.8<sup>c</sup> | 2.36 | 3.51 | 0.06<sup>d</sup> |
|       | GY | 4.0 | 2.0 | 8.1 | 2.6 | 3.25 | 1.12 | 0.29 |

<sup>a</sup>Amino acid position coded by exon 2. <sup>b</sup>Amino acid motifs significantly increased in c-ALL. <sup>c</sup>Phenotypes significantly increased in c-ALL. <sup>d</sup>Significant difference (P<0.05).
amplified sequence could be missed, and sequence variations outside this region would go undetected. For disease association studies, in which time is less important than in donor–recipient transplant matching, PCR–SSCP using group-specific amplification combines a low-resolution PCR–SSP approach, with the sequence-dependent resolving power of capillary electrophoresis. This approach was first demonstrated for DQB1 by Lo et al. (1992), and the value of group-specific amplification documented by Carrington et al. (1992). Although we have used silver staining to assign alleles, our method should lend itself to more rapid typing using fluorescent primers in conjunction with an automated sequencer.

We have not corrected our results for the number of allele combinations, so we cannot at present completely rule out that the DQB1*05 association occurred by chance. The difficulty of providing conclusive proof of an increased genetic risk due to DQB1*05 in c-ALL is not one of ascertainment, because our patients are an unbiased prospective group from a single geographical region. The problem concerns the relative rarity of this disease, despite the fact that childhood c-ALL is itself the commonest childhood malignancy. At the level of risk found here, we would have needed at least twice the number of patients to verify the association. However, our results provide a useful basis for hypothesis generation and a preliminary answer to the question of whether the DPB1*0201 association is due to linkage disequilibrium.

If genetic susceptibility to c-ALL is conferred by DQB1*05 it suggests some degree of specificity in the interaction with an environmental co-factor. Since there is no evidence from our studies so far that DPB1 or DQB1 alleles in childhood c-ALL are mutated in the germ line, we assume that the increased risk is conferred by the normal allele itself. This raises the question as to why a relatively common HLA allele should increase the risk of a previously lethal childhood disease such as c-ALL, a clear selective disadvantage to the allele. We previously suggested in the context of DPB1 that one explanation for this could be that since HLA alleles are neither necessary nor sufficient to cause leukemia they may confer protection to some numerically more important infectious agent. Thus, c-ALL high-risk HLA alleles might be less effective in protecting against a leukemogenic infection caused by molecular mimicry of the susceptibility allele by the infectious agent, but be effective against any other infection. Since the transformation of pre-B progenitor cells into c-ALL requires at least two mutations, it seems unlikely that HLA alleles determine whether a fetus will succumb to an in utero infection. This might be expected to be associated with birth abnormalities in children with leukemia.

A different interpretation is suggested by the Greaves hypothesis (Greaves and Alexander, 1993). This postulates that the chance of a second mutation in a preleukemic pre-B progenitor population is promoted by post-natal infection-induced cell division. HLA alleles associated with a risk of c-ALL might in this case be the target of, or induce, the immunostimulatory signals which lead to the increased division of the pre-leukemic population. If an infectious agent contained immunogenic peptides capable of binding to alleles at more than one HLA class II locus, this might maximise immune recognition but also enhance pre-B stimulation. Such a phenomenon might explain the apparent independence of DPB1- and DQB1-associated susceptibility to c-ALL.

We found a difference in the percentage of boys and girls with DQB1*0501 (RRMfp, 2.92), and DQB1*0602 (RRMfp, 0.24). This sex difference in the frequency of a susceptibility allele was absent in our previous analysis of DPB1 (Taylor et al., 1995). One explanation for the sex difference could be that there are subtle male–female differences in genetic susceptibility to immune-associated disease as previously suggested (Purtilo, 1979). Since there is an excess of males to female with c-ALL in our series, it is possible that X-linked immunoregulatory genes influence the ability of males and females to respond to HLA-associated immunogenic peptides.

Genotype analysis revealed a higher frequency of DQB1*0201 homozygosity in the controls than in the patients. We can exclude typing artifact due to the misidentification of heterozygotes as homozygotes as both series were typed at the same time, using the same reagents and techniques. We can also exclude increased HLA homozygosity due to consanguineous ethnic minority parents, since we excluded Asian infants from the control series. The result suggests that *0201 homozygosity may have a protective effect in c-ALL. It is of interest to note that none of the amino acid sequence motifs found in *0501, or any of the other alleles associated with an increased risk of c-ALL is also found in *0201. More specifically, the serine residue at position 30, and arginine–lysine at positions 70–71 of *0201, both differ from the motifs associated with DQB1 susceptibility to c-ALL, and may be considered as conferring protection.

The amino-acid motifs associated with an increased risk of c-ALL include glycine, histidine, valine and glutamic acid–valine. Of the four motifs at position 57, aspartic acid (Asp) is present in only 48% of children with c-ALL compared with 64% of infant controls, and is negatively associated with c-ALL. It has been known for some time that Asp7 confers resistance to insulin-dependent diabetes (Tod et al., 1987; Morel et al., 1988; Tosi et al., 1994), although the presence or absence of this motif is not sufficient to account for inherited susceptibility (Thomson et al., 1988; Kockum et al., 1993). Although there are few similarities between c-ALL and IDD among the four major susceptibility alleles, they occur in childhood, the possibility that a common infectious agent, or similar immunoregulatory defect with a different outcome is involved would repay further study.

Acknowledgements
We thank the UKCCCR, the Kay Kendall Leukaemia Fund and the Leukaemia Research Fund for financial support for this work, William Fergusson and Colin Summers for valued assistance, Ruth Carter for secretarial help, and Sandra Roe for graphics.

References
APPLE RJ, ERLICH HA, KLITZ W, MANOS MM, BECKER TM AND WHEELER CM. (1994). HLA DR-DQ associations with cervical carcinoma show papilloma virus specificity. Nature Genet., 6, 157–162.
BAISCH JM AND CAPRA JD. (1993). Linkage disequilibrium within the HLA complex does not extend into HLA-DRP. Scand. J. Immunol., 37, 503–507.
BLIN N AND STAFFORD DW. (1976). Isolation of high molecular weight DNA. Nucleic Acids Res., 3, 2302–2308.
BRESLOW NE AND LANGHOLZ B. (1983). Childhood cancer incidence: geographical and temporal variations. Int. J. Cancer, 33, 703–710.
BUGAWAN TL AND ERLICH HA. (1991). Rapid typing of HLA-DQB1 DNA polymorphism using nonradioactive oligonucleotide probes and amplified DNA. Immunogenetics, 33, 163–170.
CARRINGTON M, MILLER T, WHITE M, GERRARD B, STEWART C, DEAN M AND MANN D. (1992). Typing of HLA-DQA1 and -DQB1 using DNA single strand conformation polymorphism. Hum. Immunol., 33, 208–212.
COURT BROWN WM AND DOLL R. (1961). Leukemia in childhood and young adult life. Trends in mortality in relation to aetiology. Br. Med. J., 3, 981–988.
ERLICH HA AND ARNHEIM N. (1992). Genetic analysis using the polymerase chain reaction. Annu. Rev. Genet., 26, 479–506.
GREAVES MF AND ALEXANDER FE. (1993). An infectious etiology for common acute lymphoblastic leukemia in childhood? Leukemia, 7, 349–360.
GREAVES MF, PEGRAM SM AND CHAN LC. (1985). Collaborative group study of the epidemiology of acute lymphoblastic leukemia subtypes: background and first report. Leuk. Res., 9, 715–733.
 GREAVES MF, CHAN LC, FORD AM, PEGRAM SM AND WIEDEMANN LM. (1991). Etiological mechanisms in childhood acute lymphoblastic leukemia. In Childhood Leukemia: Present Problems and Future Prospects. Proceedings of the Second International Symposium on Children's Cancer, Tokyo, 1989. pp. 3 – 22.
Kluwer: Dordrecht.

KINLEN LJ, CLARKE K AND HUDSON C. (1990). Evidence from population mixing in British new towns 1946 – 85 of an infective basis for childhood leukemia. Lancet, 336, 577 – 582.

KNEALE GW. (1971). Excess sensitivity of pre-leukaemias to pneumonia. A model situation for studying the interaction of infectious disease with cancer. Br. J. Prev. Soc. Med., 25, 152 – 159.

KOCKUM I, WASSMUTH R, HOLMBERG E, MICHELSBON B AND LERNMARK A. (1993). HLA-DQ primarity confers protection and HLA-DR susceptibility in type I (insulin-dependent) diabetes studied in population-based affected families and controls. Am. J. Hum. Genet., 53, 150 – 167.

LEE JE, REVEILLE JD, ROSS MI AND PLATSOUCAS CD. (1994). HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int. J. Cancer, 59, 510 – 513.

LINET MS AND DEVESA SS. (1991). Descriptive epidemiology of childhood leukemia. Br. J. Cancer, 63, 424 – 429.

LO YMD, PATEL P, MEHAL WZ, FLEMING KA, BELL JI AND WAINSCOAT JS. (1992). Analysis of complex genetic systems by ARMS-SSCP: application to HLA genotyping. Nucleic Acids Res., 20, 1005 – 1009.

MOLKENTIN J, GORSKI J AND BAXTER-LOWE LA. (1991). Detection of 14 HLA-DQB1 alleles by oligotyping. Hum. Immunol., 31, 114 – 122.

MOREL PA, DORMAN JS, TODD JA, McDEVITT HO AND TRUCCO M. (1988). Aspartic acid at position 57 of the HLA-DQ β chain protects against type I diabetes; a family study. Proc. Natl Acad. Sci., 85, 8111 – 8115.

OLERUP O, ALDENER A AND FOGDELL A. (1993). HLA-DQβ1 and –DQA1 typing by PCR amplification with sequence specific primers (PCR-SSP) in 2 hours. Tissue Antigens, 41, 119 – 134.

ORITA M, IWAHANA H, KANAZAWA H, HAYASHI K AND SEKIYA T. (1989). Detection of polymorphisms of human DNA by gel electrophoresis as a single strand conformation polymorphism. Proc. Natl Acad. Sci. USA, 86, 2766 – 2770.

PARKIN DM, STILLER CA, DRAPER GJ AND BIEBER CA. (1988). The international incidence of childhood cancer. Int. J. Cancer, 42, 511 – 520.

PURITOLO DT. (1979). X-associated immunocompetence. Lancet, i, 327.

SALAZAR M, DEULOFLEUT R, BUNIS JJ, BING DH AND YUNIS EJ. (1993). A fast PCR-SSP method for HLA-DQ genic typing. Tissue Antigens, 41, 102 – 106.

STEWART A. (1961). Aetiology of childhood malignancies. Congenitally determined leukemias. Br. Med. J., i, 452 – 460.

STEWART A AND KNEALE GW. (1969). Role of local infections in the recognition of haemopoietic neoplasms. Nature, 223, 741 – 742.

SUMMERS CW, FERGUSSON WD, GOKHALE DA AND TAYLOR M. (1992). Donor-recipient bone marrow matching by single stranded conformation polymorphism analysis. Lancet, 339, 621.

TAYLOR GM. (1994). Immunogenetics and the aetiology of childhood leukaemia. Arch. Dis. Child., 70, 77 – 81.

TAYLOR GM, ROBINSON MD, BINCHY A, BIRCH JM, STEVENS RF, JONES PM, CARR T, DEARDEN S AND GOKHALE DA. (1995). Preliminary evidence of an association between HLA-DPB1*0201 and childhood common acute lymphoblastic leukemia supports an infectious aetiology. Leukemia, 9, 440 – 443.

THOMSON G, ROBINSON WP, KUHNER MK, JOE S, MACDONALD MJ, GOTTSCHALL JL, BARBOSA J, RICH SS, BERTRAMS J, BAUR MP, PARTANEN J, TAIT BD, SCHOBER E, MAYR WR, LUDVIGSON J, LINDBLOM B, FARID NR, THOMPSON C AND DESCHAPS I. (1988). Genetic heterogeneity, modes of inheritance, and risk estimates for a joint study of Caucasians with insulin-dependent diabetes mellitus. Am. J. Hum. Genet., 43, 799 – 816.

TODD JA, BELL JI AND McDEVITT HO. (1987). HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature, 329, 599 – 604.

TOSI G, BRUNELLI S, MANTERO G, MAGALINI AR, SOFFIATI M, PINELLI L, TRIDENTE G AND ACCOLLA RS. (1994). The complex interplay of the DQB1 and DQA1 loci in the generation of the susceptible and protective phenotype for insulin-dependent diabetes mellitus. Mol. Immunol., 31, 429 – 437.

TROWSDALE J AND CAMPBELL RD. (1992). Complexity of the major histocompatibility complex. Eur. J. Immunogenet., 19, 45 – 55.

UNO H, KAWANO K, MATSUOKA H AND TSUDA K. (1988). HLA and adult T cell leukaemia: HLA-linked genes controlling susceptibility to human T cell leukaemia virus type I. Clin. Exp. Immunol., 71, 211 – 216.